These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 26026107)

  • 1. Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study.
    Shah BK; Khanal A
    Anticancer Res; 2015 Jun; 35(6):3437-40. PubMed ID: 26026107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second primary malignancies in adult acute myeloid leukemia--A US population-based study.
    Ghimire KB; Shah BK
    Anticancer Res; 2014 Jul; 34(7):3855-9. PubMed ID: 24982414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second Primary Malignancy in Anal Carcinoma--A US Population-based Study.
    Shah BK; Budhathoki N
    Anticancer Res; 2015 Jul; 35(7):4131-4. PubMed ID: 26124366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
    Hisada M; Chen BE; Jaffe ES; Travis LB
    J Natl Cancer Inst; 2007 Feb; 99(3):215-22. PubMed ID: 17284716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
    Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
    Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.
    Tward JD; Wendland MM; Shrieve DC; Szabo A; Gaffney DK
    Cancer; 2006 Jul; 107(1):108-15. PubMed ID: 16708354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merkel cell carcinoma and multiple primary cancers.
    Howard RA; Dores GM; Curtis RE; Anderson WF; Travis LB
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1545-9. PubMed ID: 16896047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.
    Brown AP; Chen J; Hitchcock YJ; Szabo A; Shrieve DC; Tward JD
    J Clin Endocrinol Metab; 2008 Feb; 93(2):504-15. PubMed ID: 18029468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
    Khanal A; Budhathoki N; Singh VP; Shah BK
    Anticancer Res; 2017 Apr; 37(4):2033-2036. PubMed ID: 28373478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations.
    Brown AP; Neeley ES; Werner T; Soisson AP; Burt RW; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):127-35. PubMed ID: 19910129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.
    Chien SH; Liu CJ; Hong YC; Teng CJ; Hu YW; Ku FC; Yeh CM; Chiou TJ; Gau JP; Tzeng CH
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):1995-2004. PubMed ID: 25971624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
    Moser EC; Noordijk EM; van Leeuwen FE; Baars JW; Thomas J; Carde P; Meerwaldt JH; van Glabbeke M; Kluin-Nelemans HC
    Haematologica; 2006 Nov; 91(11):1481-8. PubMed ID: 17043014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up.
    Tadmor T; Liphshitz I; Silverman B; Polliack A
    Hematol Oncol; 2017 Dec; 35(4):599-607. PubMed ID: 27238496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes.
    Herr MM; Schonfeld SJ; Dores GM; Engels EA; Tucker MA; Curtis RE; Morton LM
    Blood Adv; 2019 Jul; 3(13):1961-1969. PubMed ID: 31262739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second primary malignancies after ocular adnexal lymphoma diagnosis.
    Loya A; Ramachandran V; Ayaz T; Weng CY
    BMC Ophthalmol; 2021 Apr; 21(1):162. PubMed ID: 33827494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of subsequent primary malignancies after dermatofibrosarcoma protuberans diagnosis: a national study.
    Kurlander DE; Martires KJ; Chen Y; Barnholtz-Sloan JS; Bordeaux JS
    J Am Acad Dermatol; 2013 May; 68(5):790-6. PubMed ID: 23261548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merkel cell carcinoma: incidence, mortality, and risk of other cancers.
    Kaae J; Hansen AV; Biggar RJ; Boyd HA; Moore PS; Wohlfahrt J; Melbye M
    J Natl Cancer Inst; 2010 Jun; 102(11):793-801. PubMed ID: 20424236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry.
    Rihani R; Bazzeh F; Faqih N; Sultan I
    Cancer; 2010 Sep; 116(18):4385-94. PubMed ID: 20549819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.